Handa Oncol Company Profile

HANDA ONCOL has one approved drug.

There are six US patents protecting HANDA ONCOL drugs.

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Handa Oncol	OMCAZIO	cabozantinib laurylsulfate	CAPSULE;ORAL	220613-003	Sep 3, 2026		RX	Yes	Yes	12,552,749	⤷ Start Trial				⤷ Start Trial
Handa Oncol	OMCAZIO	cabozantinib laurylsulfate	CAPSULE;ORAL	220613-002	Sep 3, 2026		RX	Yes	No	12,516,025	⤷ Start Trial				⤷ Start Trial
Handa Oncol	OMCAZIO	cabozantinib laurylsulfate	CAPSULE;ORAL	220613-001	Sep 3, 2026		RX	Yes	No	12,516,025	⤷ Start Trial				⤷ Start Trial
Handa Oncol	OMCAZIO	cabozantinib laurylsulfate	CAPSULE;ORAL	220613-002	Sep 3, 2026		RX	Yes	No	12,552,567	⤷ Start Trial				⤷ Start Trial
Handa Oncol	OMCAZIO	cabozantinib laurylsulfate	CAPSULE;ORAL	220613-003	Sep 3, 2026		RX	Yes	Yes	12,552,567	⤷ Start Trial				⤷ Start Trial
Handa Oncol	OMCAZIO	cabozantinib laurylsulfate	CAPSULE;ORAL	220613-002	Sep 3, 2026		RX	Yes	No	12,552,749	⤷ Start Trial				⤷ Start Trial
Handa Oncol	OMCAZIO	cabozantinib laurylsulfate	CAPSULE;ORAL	220613-002	Sep 3, 2026		RX	Yes	No	12,064,430	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Subscribe to access the full database, or Start Trial
Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2213661	220 50007-2014	Slovakia	⤷ Start Trial	PRODUCT NAME: CABOZANTINIB; REGISTRATION NO/DATE: EU/1/13/890/001 - EU/1/13/890/003 20140326
2213661	PA2014033	Lithuania	⤷ Start Trial	PRODUCT NAME: CABOZANTINIBUM; REGISTRATION NO/DATE: EU/1/13/890/001 - EU/1/13/890/003 20140321
2213661	300678	Netherlands	⤷ Start Trial	PRODUCT NAME: CABOZANTINIB, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT; REGISTRATION NO/DATE: EU/1/13/890/001-003 20140326
2213661	132014902289810	Italy	⤷ Start Trial	PRODUCT NAME: CABOZANTINIB(COMETRIQ); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/13/890/001,002,003, 20140326
2213661	14C0067	France	⤷ Start Trial	PRODUCT NAME: CABOZANTINIB ET TOUTE FORME THERAPEUTIQUEMENT EQUIVALENTE COUVERTE PAR LE BREVET DE BASE,INCLUANT SES SELS PHARMACEUTIQUEMENT EQUIVALENTS.; REGISTRATION NO/DATE: EU/1/13/890 20140326
2213661	122014000091	Germany	⤷ Start Trial	PRODUCT NAME: CABOZANTINIB UND JEDES THERAPEUTISCHE AEQUIVALENT HIERVON WIE DURCH DAS GRUNDPATENT GESCHUETZT, EINSCHLIESSLICH PHARMAZEUTISCH ANNEHMBARER SALZE; REGISTRATION NO/DATE: EU/1/13/890/001-003 20140321
2213661	CR 2014 00039	Denmark	⤷ Start Trial	PRODUCT NAME: CABOZANTINIB, INKLUSIVE FARMACEUTISK ACCEPTABLE SALTE HERAF, HERUNDER CABOZANTINIB (S)-MALAT; REG. NO/DATE: EU/1/13/890/001-003 20140326
>Patent Number	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration	>SPC Description

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.